Friday, 15 Feb 2019

PsA/SpA

Date Typesort ascending Title Save
16 Nov 2017 Social IL-17–producing αβ T cell clones with psoriasis-specific antigen receptors exist in clinically resolved psoriatic s… https://t.co/Lj4B4dQ25N
26 Jul 2015 Social RT@DrPetryna Interesting read. Role of IL23 pathway and Innate Lymphoid Cells in pathogenesis of AS and IBS - http://t.co/EXAuGRvnfz
21 Oct 2016 Social Psoriasis pts failing TNF inhib. shows secondary failure more likely than primary failure to respond to a 2nd TNFi https://t.co/xEFhZZv9VQ
07 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter. https://t.co/1EMk9QsW3V
16 Jun 2018 Social RT @RonanTKavanagh: @Janetbirdope @RheumNow Fits with my experience. And Ps A seems more forgiving of breaks from treatment. Usually works…
05 Nov 2017 Social RT @japaoli19: Low dose CT detects more spinal progression vs xray in AS measured by ct syndesmophyte sc #582 #ACR17 @rheumnow https://t.…
20 Jan 2017 Social Small prospective study shows a potential benefit of Vedolizumab in IBD-associated SpA. 46% pts improved @drpetryna https://t.co/pgoKO8ZabS
03 Aug 2017 Social FDA Arthritis Advisory Panel votes 10-1 in favor of approving tofacitinib (Xeljanz) for use in Psoriatic athritis. FDA decision pending.
09 Sep 2018 Social Excellent open review of obesity's influence on disease onset (RA, PsA), pathogenesis, disease progression, functional consequences and treatment interference. https://t.co/xaOkBrWDR4
22 Mar 2018 Social FDA Approves Ilumya (tildrakizumab for Moderate-to-Severe Plaque Psoriasis. It binds p19 subunit of IL-23, inhibiting binding to IL-23 receptor. Given as 100 mg sc at Wk 0, 4 & q 12wks; 2nd IL-23 inhib approved for Pso. https://t.co/q9bQTVqN0t
29 Apr 2016 Social Extensive skin psoriasis is a risk factor for Psoriatic Arthritis - other risk factors nail dz, obesity & smoking https://t.co/NZAqi0RJDB
06 Nov 2017 Social Plenary abst#1787 Landawe presents Atlas 5 study, continuation of ADA is assoc w/ signif less flares in nr-AxSpApts… https://t.co/O1xSQ6nafD
17 Feb 2017 Social RT @DrRachelTate: RAPID3 as a potential useful tool for PsA. Arthur Kavanaugh, MD and Eric Ruderman, MD #rwcs2017 @RWCSmtg @RheumNow https:…
16 Oct 2017 Social Looking at 2 different datasets, having PsA confers a 30+% risk of Cardiovascular dz https://t.co/0OcGOUDg9T
18 Jun 2015 Social Arthritis mutilans review & defined:digital telescoping/shortening, flail jts, xray resorption, pencil-in-cup change http://t.co/PXq9iPBQyZ
27 Jun 2016 Social RAPID3 gives similar outcome info to BASDAI and ASDAS in a cross sectional study of 85 AS patients https://t.co/uIfXJpB5s3
24 Feb 2017 Social Study of >43K Pso, PsA, AS pts shows 14-34% increase risk for depression; but not for suicide or suicidal ideation. https://t.co/STsQikW5pN
13 Jun 2018 Social Lindstrom studied their Swedish AS registry and found that While the presence of Uveitis was assoc w/ better TNFi responses; all other comorbidities yielded lesser TNFi responses. #EULAR2018 @RheumNow OP0023 https://t.co/bltRC4khbL
22 Oct 2018 Social RT @japaoli19: Abstract 1631 20% incidence of uveitis in SpA with IBD phenotype having the highest incidence #ACR18 @rheumnow https://t.co…
07 Nov 2017 Social RT @DrPetryna: FUTURE5: Cosentyx clinically&radiofraph superior toPBO. mTSS non-progression 88%Cosentyx vs73% PBO #L17 #acr17 @RheumNow htt…